D.E. Shaw & Co
ADAP

D.E. Shaw & Co’s Adaptimmune Therapeutics ADAP Stock Holding History

D.E. Shaw & Co’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-26,579
Closed -$40K – 3929
2019
Q3 		$40K Sell
26,579
-51,411
-66% -$120K ﹤0.01% 3736
2019
Q2 		$314K Sell
77,990
-216,583
-74% -$883K ﹤0.01% 3299
2019
Q1 		$1.27M Buy
294,573
+80,412
+38% +$374K ﹤0.01% 2462
2018
Q4 		$1.23M Buy
+214,161
New +$1.58M ﹤0.01% 2517
2018
Q2 		– Sell
-31,367
Closed -$352K – 3668
2018
Q1 		$352K Sell
31,367
-50,253
-62% -$440K ﹤0.01% 3067
2017
Q4 		$545K Sell
81,620
-119
-0.1% -$919 ﹤0.01% 2934
2017
Q3 		$669K Buy
81,739
+46,243
+130% +$289K ﹤0.01% 2745
2017
Q2 		$159K Sell
35,496
-56,371
-61% -$295K ﹤0.01% 3224
2017
Q1 		$506K Sell
91,867
-8,656
-9% -$37.9K ﹤0.01% 2730
2016
Q4 		$407K Buy
100,523
+18,216
+22% +$87.4K ﹤0.01% 2968
2016
Q3 		$580K Buy
82,307
+71,177
+640% +$543K ﹤0.01% 2718
2016
Q2 		$91K Sell
11,130
-702
-6% -$6.61K ﹤0.01% 3263
2016
Q1 		$96K Buy
+11,832
New +$96.8K ﹤0.01% 3286
2015
Q3 		– Sell
-15,232
Closed -$279K – 3697
2015
Q2 		$279K Buy
+15,232
New +$261K ﹤0.01% 3444

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

D.E. Shaw & Co's ADAP Position: Q4 2019 in Review

D.E. Shaw & Co sold out of Adaptimmune Therapeutics (ADAP) in Q4 2019, closing a stake of 26,579 shares — an estimated $40K sold.

D.E. Shaw & Co first reported a position in ADAP in Q2 2015 and held it in 14 quarters. The position peaked at $1.27M in Q1 2019. 43 funds tracked by Wall St. Rank hold ADAP as of Q4 2019.

  • D.E. Shaw & Co reported no remaining Adaptimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
  • D.E. Shaw & Co sold 26,579 Adaptimmune Therapeutics shares in Q4 2019, an estimated $40K.
  • D.E. Shaw & Co first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 14 quarters.
  • D.E. Shaw & Co's Adaptimmune Therapeutics position peaked at $1.27M in Q1 2019.
  • 43 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2019.

Based on D.E. Shaw & Co's 13F filing for Q4 2019, filed 14 Feb 2020.